SCYNEXIS Inc. Enters Material Definitive Agreement

TL;DR

SCYNEXIS signed a big deal, details to come.

AI Summary

SCYNEXIS, Inc. filed an 8-K on October 15, 2025, reporting an entry into a material definitive agreement on October 14, 2025. The filing does not disclose specific details of the agreement, names of parties involved, or any associated dollar amounts.

Why It Matters

This filing indicates a significant new contract or partnership for SCYNEXIS, Inc., which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in this 8-K filing creates uncertainty about the nature and impact of the material definitive agreement.

Key Players & Entities

• SCYNEXIS, Inc. (company) — Registrant
• October 14, 2025 (date) — Date of earliest event reported
• October 15, 2025 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SCYX The Nasdaq Global Ma
• $22 million — nate the MARIO Study and will receive a $22 million payment from GSK. SCYNEXIS will not rec
• $2.3 million — IO Study but will receive an additional $2.3 million payment from GSK in connection with the

Filing Documents

• scyx-20251014.htm (8-K) — 46KB
• 0001178253-25-000006.txt ( ) — 149KB
• scyx-20251014.xsd (EX-101.SCH) — 24KB
• scyx-20251014_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Binding Memorandum of Understanding for Amendment to Exclusive License Agreement with GSK On October 14, 2025, SCYNEXIS, Inc. ("SCYNEXIS") and GlaxoSmithKline Intellectual Property (No. 3) Limited ("GSK") entered into a binding memorandum of understanding (the "Binding 2025 MOU") for amendment to the exclusive license agreement between SCYNEXIS and GSK, dated March 30, 2023, as amended by a binding memorandum of understanding on December 26, 2023 (the "Binding 2023 MOU") (the exclusive license agreement and Binding 2023 MOU, together with the associated Transitional Manufacturing and Supply Agreement, the "Exclusive License Agreement"). Pursuant to the terms of the Exclusive License Agreement, SCYNEXIS granted GSK an exclusive (even as to SCYNEXIS and its affiliates), royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME , for all indications, in all countries other than Greater China and certain other countries already licensed to third parties. The terms of the Exclusive License Agreement are further described in SCYNEXIS's Current Reports on Form 8-K filed with the Securities and Exchange Commission on March 30, 2023 and January 2, 2024. As previously disclosed, there was a disagreement between SCYNEXIS and GSK regarding the Phase 3 MARIO study of ibrexafungerp for the treatment of invasive candidiasis (the "MARIO Study"). The parties have now resolved the disagreement as detailed in the Binding 2025 MOU, pursuant to which SCYNEXIS has agreed to promptly wind-down and terminate the MARIO Study and will receive a $22 million payment from GSK. SCYNEXIS will not receive any additional milestone payments from GSK specifically associated with the MARIO Study but will receive an additional $2.3 million payment from GSK in connection with the wind-down and termination activities. GSK has reiterated its commitm

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SCYNEXIS, Inc. Date: October 15, 2025 By: /s/ David Angulo Name: Its: David Angulo, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR